Thomas G Wiggans bought $18k of JSPR
director at Jasper Therapeutics, Inc.. 30,000 shares at an average of $0.61, traded Nov 16, 2023, filed Nov 20, 2023.
Score components
- +15RoleDirector
- 0Trade size$18k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context78% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.7%, 3m +195.5%, 6m +262.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-23-088896, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 16, 2023 | POpen-market purchase Voting Common Stock | +10,000 | $0.60 | $5,965 | 10,000 | Nov 20, 2023 |
| Nov 17, 2023 | POpen-market purchase Voting Common Stock | +10,000 | $0.60 | $5,966 | 20,000 | Nov 20, 2023 |
| Nov 20, 2023 | POpen-market purchase Voting Common Stock | +10,000 | $0.63 | $6,309 | 30,000 | Nov 20, 2023 |
Related signals
Other insiders at Jasper Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 64Notable | Jasper Therapeutics, Inc. | Judith Anne Shizuru director | $100k 41,000 shares | +35% | |
| 78Notable | Jasper Therapeutics, Inc. | Ron Martell President and CEO | $100k 41,000 shares | +124% | |
| 63Notable | Jasper Therapeutics, Inc. | Svetlana Lucas director | $49k 20,000 shares | - | |
| 66Notable | Jasper Therapeutics, Inc. | Thomas G Wiggans director | $100k 41,000 shares | - | |
| 0Weak | Jasper Therapeutics, Inc. | Jeetinder Singh Mahal Chief Operating Officer | $20k 900 shares | -3% | |
| 0Weak | Jasper Therapeutics, Inc. | Jeetinder Singh Mahal Chief Operating Officer | $24k 900 shares | -3% | |
| 50Moderate | Jasper Therapeutics, Inc. | Carlyle Holdings I GP Inc. owner | $2.5M 190,000 shares | +22% | |
| 50Moderate | Jasper Therapeutics, Inc. | Velan Capital Investment Management LP owner | $4.5M 350,000 shares | +42% | |
| 34Weak | JSPRbuy Jasper Therapeutics, Inc. | Thomas G Wiggans director | $6,486 10,000 shares | +25% | |
| 34Weak | JSPRbuy Jasper Therapeutics, Inc. | Thomas G Wiggans director | $6,383 10,000 shares | +33% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.